Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. A disproportionately high burden (>80%) occurs in low- and middle-income countries. In addition to mortality, CVD significantly contributes to disability-adjusted life years (DALYs), particularly among older populations in developing regions.
A major pathological basis of CVD is atherosclerosis, characterized by progressive lipid deposition and inflammatory changes in arterial walls, leading to coronary artery disease, myocardial infarction, and stroke. Hypercholesterolaemia is one of the most important modifiable metabolic risk factors driving atherogenesis.
Epidemiology of hypercholesterolaemia
Elevated cholesterol levels contribute to approximately one-third of global ischaemic heart disease burden. Globally, a substantial proportion of adults exhibit raised serum cholesterol, with higher prevalence observed in high-income countries (>50%) compared to low-income settings (~25%). However, rapid urbanization and lifestyle transitions have led to a rising trend in dyslipidaemia in developing populations as well.
Lipid metabolism and atherosclerosis
Cholesterol is a lipid molecule essential for cell membrane integrity and serves as a precursor for bile acids and steroid hormones. In plasma, it is transported via lipoproteins:
- Low-density lipoprotein cholesterol (LDL-C): atherogenic “bad cholesterol”
- High-density lipoprotein cholesterol (HDL-C): protective “good cholesterol”
Total cholesterol comprises LDL-C, HDL-C, and triglycerides, with LDL-C contributing approximately 60–70% of circulating cholesterol. Hypercholesterolaemia is defined by elevated LDL-C and/or total cholesterol with relatively reduced HDL-C levels, predisposing to endothelial dysfunction and plaque formation.
Risk factors and clinical thresholds
Major contributors to dyslipidaemia include:
- Diet rich in saturated fats and cholesterol
- Obesity and physical inactivity
- Sedentary lifestyle and metabolic disorders
Guidelines from the National Cholesterol Education Program (NCEP ATP III) categorized LDL-C levels based on risk, while newer ACC/AHA guidelines emphasize risk-based stratification for statin therapy, prioritizing cardiovascular risk profiles over fixed lipid targets.
Current management strategies
First-line management includes lifestyle modification:
- Dietary fat restriction
- Smoking cessation
- Regular physical activity
- Weight management
- Blood pressure control
Pharmacotherapy primarily includes statins, which reduce LDL-C by 25–40% and cardiovascular events by 30–40%. Additional agents include fibrates, niacin, and cholesterol absorption inhibitors (e.g., Ezetimibe). Despite efficacy, long-term therapy may be associated with adverse effects and variable adherence.
Description of the intervention
Ayurvedic concept of lipid disorders:
Ayurveda conceptualizes health as a balanced state of body, mind, and spirit. Hypercholesterolaemia does not have a direct classical equivalent; however, it is closely correlated with Medovriddhi and Medodushti, representing pathological accumulation and dysfunction of Meda Dhatu (adipose tissue).1
Dosha and dhatu involvement:
According to Ayurvedic physiology:
- Meda Dhatu is derived from Prithvi and Ap Mahabhutas
- It is functionally associated with Kapha Dosha
- It possesses Snigdha, Guru, and Picchila gunas
Meda Dhatu contributes to lubrication (Sneha), energy storage, and structural integrity. However, imbalance leads to excessive fat accumulation and metabolic dysfunction.
Etiological factors:
Pathogenesis of Medodushti is linked to:
- Excess intake of Guru, Snigdha, and Madhura foods
- Sedentary lifestyle and lack of exercise
- Overeating and irregular dietary habits
- Kapha-aggravating behaviors
This results in impaired Agni (digestive and metabolic fire) and improper dhatu formation, leading to systemic metabolic disorders including Prameha (diabetes) and dyslipidaemia.
Ayurvedic therapeutic approach
Management is multimodal and includes:
- Dietary regulation (Pathya-Apathya)
- Physical activity and yoga
- Langhana (lightening therapies)
- Panchakarma (detoxification procedures)
- Herbal and mineral formulations
Key lipid-lowering Ayurvedic herbs
Commonly used hypolipidaemic herbs include:
- Guggulu (Commiphora mukul)
- Arjuna (Terminalia arjuna)
- Garlic (Allium sativum)
- Triphala formulations
- Shilajit and other Rasayana drugs
These are often combined in polyherbal preparations for synergistic effects.
Mechanisms of action of Ayurvedic herbal interventions
Biochemical and molecular basis:
- Experimental evidence suggests that Ayurvedic lipid-lowering agents may act through:
- Modulation of lipid metabolism pathways
- Regulation of hepatic cholesterol synthesis
- Enhancement of LDL receptor activity
- Antioxidant-mediated protection against LDL oxidation
- Anti-inflammatory cytokine modulation
Representative mechanistic examples:
- Guggulu (Commiphora mukul): FXR antagonism, enhanced bile acid metabolism, increased LDL clearance
- Terminalia arjuna: antioxidant flavonoids reducing LDL oxidation and endothelial damage
- Triphala: inhibition of digestive lipases and improvement in gut microbiota composition
- Shilajit: mitochondrial activation and metabolic regulation
Safety considerations
Adverse effects and limitations:
- Although generally well tolerated, reported concerns include:
- Gastrointestinal discomfort
- Headache and mild dermatological reactions
- Rare heavy metal contamination in improperly processed formulations
Drug interaction potential:
Certain formulations may influence cytochrome P450 enzymes, potentially altering the pharmacokinetics of conventional drugs such as antihypertensives and cardiovascular agents.
Clinical relevance and evidence status
Current evidence base:
Clinical and preclinical studies suggest potential benefits of Ayurvedic lipid-lowering formulations in:
- Reduction of serum LDL-C and triglycerides
- Improvement in HDL-C levels
- Support in metabolic syndrome management
- Reduction in inflammatory and oxidative stress markers
However, variability in study design and standardization limits definitive conclusions.
Research gaps:
Key areas requiring further investigation include:
- Large-scale randomized controlled trials
- Standardization of herbal formulations
- Long-term safety and pharmacovigilance
- Mechanistic molecular studies
Conclusion
Ayurvedic herbal interventions for hypercholesterolaemia, grounded in the concepts of Medodushti and Kapha imbalance, offer a multi-targeted therapeutic approach involving lipid modulation, metabolic regulation, and anti-inflammatory activity. While emerging evidence supports their potential cardiovascular benefits, robust clinical validation and standardization are essential for their integration into evidence-based dyslipidaemia management.2
References:
- Verma R. REVIEW ARTICLE ON HYPERCHOLESTEROLEMIA. International Journal of Current Research. Vol. 12, Issue, 05, pp.10434-10440, May, 2020. DOI: https://doi.org/10.24941/ijcr.38625.05.2020. https://www.researchgate.net/publication/342850854_REVIEW_ARTICLE_ON_HYPERCHOLESTEROLEMIA
- Gyawali D, Schneider RH, Orme‐Johnson DW, Ramaratnam S. Ayurvedic herbal preparations for hypercholesterolaemia. Cochrane Database Syst Rev. 2019;2019(3):CD012076. Published 2019 Mar 15. doi:10.1002/14651858.CD012076.pub2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6417910/